Atossa Therapeutics Celebrates Significant CDC Grant
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical firm dedicated to breast cancer prevention and treatment, is thrilled to announce that Dr. Tessa Cigler, a valued Board Director, and her team at Weill Cornell Medicine have received a notable grant. This CDC-funded grant, valued at $2.3 million over five years, is aimed at improving breast cancer care access and outcomes specifically for young patients in New York City.
Empowering Young Breast Cancer Patients
Dr. Cigler, who plays a pivotal role as a co-principal investigator in this initiative, is set to collaborate with Dr. Vered Stearns and a diverse team at Weill Cornell Medicine. Their mission is to cater to the distinctive challenges faced by young breast cancer patients, particularly those hailing from various racial, ethnic, and socioeconomic backgrounds. The program is designed to enhance care coordination and offer culturally relevant resources, thereby fostering an environment where patients and their caregivers can thrive both physically and emotionally.
Acknowledging Leadership and Commitment
Dr. Steven Quay, M.D., Ph.D., FCAP, CEO of Atossa Therapeutics, expressed immense pride in Dr. Cigler’s dedication and the significant strides she has made in breast cancer care. He remarked, "Dr. Cigler's commitment to reducing health disparities through innovative solutions is commendable. Her extensive knowledge and leadership have not only benefited our board but are also impacting the broader healthcare community. Atossa is dedicated to supporting initiatives that promote effective and inclusive breast cancer treatment strategies."
Collaborative Efforts for Improved Patient Care
Atossa Therapeutics extends hearty applause to the Weill Cornell Medicine team and other partners for their relentless pursuit of more effective and equitable breast cancer care. The collaboration aims for significant improvements in the lives of young breast cancer patients and their families by providing better access to care and meaningful support.
Innovative Approaches in Oncology
Atossa Therapeutics is making waves in the biopharmaceutical industry with its focus on developing new treatments for breast cancer. In particular, the company’s research around (Z)-endoxifen demonstrates potential breakthroughs in how breast cancer is treated, representing exciting advancements in oncology.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is known for its commitment to tackling significant unmet medical needs in oncology. Through innovative research and development efforts, the company focuses on using (Z)-endoxifen effectively for breast cancer prevention and treatment. For further details about their initiatives, visit www.atossatherapeutics.com.
Company Contact Information
For additional inquiries, interested parties can reach out to:
Michael Parks,
VP, Investor and Public Relations,
Phone: 484-356-7105,
Email: michael.parks@atossainc.com.
Frequently Asked Questions
What is the purpose of the CDC grant awarded to Dr. Tessa Cigler?
The grant is intended to enhance breast cancer care access and improve outcomes for young patients in New York City.
Who is involved in the initiative alongside Dr. Cigler?
Dr. Vered Stearns and a multidisciplinary team at Weill Cornell Medicine are collaborating on this initiative.
What are the key focus areas of the program?
The program aims to improve care coordination, provide culturally relevant resources, and introduce targeted interventions for young breast cancer patients.
How does Atossa Therapeutics support breast cancer initiatives?
Atossa Therapeutics supports innovative approaches to improving breast cancer treatment and programs that foster equity and inclusivity in patient care.
Where can I find more information about Atossa Therapeutics?
More information can be found on their official website, www.atossatherapeutics.com.
